Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

19
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
19
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

871
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
871
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

625
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
625

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arctigenin as a promising anticancer agent: a comprehensive review of molecular mechanisms across major carcinomas.

Frontiers in pharmacology·2026
Same author

Care Gap: Identifying and Bridging Barriers in Primary Palliative Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Decoding the Mystery of Sugarcane Genome-Based Breeding: Current Advancements, Strategies, and Future Challenges.

Plant, cell & environment·2026
Same author

Evaluation of the TCGA-Surrogate (ProMisE) Molecular Classification and Clinical Features of Endometrial Carcinoma: A Study of 97 Cases from China.

International journal of women's health·2026
Same author

RWC Update: Modern One Health Approaches to Novel Challenges in Infectious Uveitis-Parasitic, Fungal and Mycobacterial Uveitis (Part 2); Management of 180° Iridodialysis With Aphakia and Total Hyphema; Retinal Astrocytic Hamartoma.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Management and outcomes of sigmoid volvulus: a retrospective cohort study of 46 patients at a tertiary care center.

International journal of surgery case reports·2026

Related Experiment Video

Updated: Sep 3, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.9K

When Will Fondaparinux Induce Thrombocytopenia?

Li-Yu Chen1,2, Nida Khan1,3, Annerose Lindenbauer1

  • 1Institute for Bioprocessing and Analytical Measurement Techniques, 37308 Heiligenstadt, Germany.

Bioconjugate Chemistry
|July 25, 2022
PubMed
Summary

Fondaparinux can cause thrombocytopenia (low platelets) by forming complexes with PF4, which bind to HIT-like antibodies. This explains why Fondaparinux-induced thrombocytopenia (FIT) is controversial, depending on drug concentration.

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Related Experiment Videos

Last Updated: Sep 3, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

13.9K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Area of Science:

  • Pharmacology
  • Hematology
  • Immunology

Background:

  • Fondaparinux is a safe anticoagulant alternative for patients with heparin-induced thrombocytopenia (HIT).
  • Contradictory reports exist regarding Fondaparinux-induced thrombocytopenia (FIT), with its mechanism remaining unclear.

Purpose of the Study:

  • To investigate the mechanism underlying Fondaparinux-induced thrombocytopenia (FIT).
  • To clarify the controversy surrounding FIT occurrence in patients.

Main Methods:

  • Dynamic light scattering
  • Immunosorbent assays
  • Platelet aggregation assays
  • Confocal laser scanning microscopy
  • Flow cytometry

Main Results:

  • Fondaparinux forms stable complexes with Platelet Factor 4 (PF4) at specific concentrations.
  • These complexes facilitate the binding of HIT-like monoclonal KKO antibody.
  • Enhanced platelet aggregation and activation were observed.

Conclusions:

  • Fondaparinux concentration is critical in forming PF4 complexes that trigger platelet activation.
  • The study proposes a model explaining FIT based on PF4:Fondaparinux ratios.
  • This clarifies conflicting clinical observations of FIT.